Immunic, Inc. (NASDAQ:IMUX) Sees Significant Growth in Short Interest

Immunic, Inc. (NASDAQ:IMUXGet Free Report) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 5,640,000 shares, a growth of 14.9% from the December 31st total of 4,910,000 shares. Based on an average daily volume of 976,100 shares, the days-to-cover ratio is currently 5.8 days.

Insider Activity

In other Immunic news, Director Richard Alan Rudick purchased 87,300 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was bought at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the acquisition, the director now owns 87,300 shares of the company’s stock, valued at approximately $100,395. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares during the period. State Street Corp lifted its stake in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares during the period. Jane Street Group LLC increased its stake in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after acquiring an additional 38,553 shares during the period. Virtu Financial LLC acquired a new position in shares of Immunic during the third quarter valued at approximately $50,000. Finally, HB Wealth Management LLC bought a new stake in Immunic during the fourth quarter worth approximately $81,000. Institutional investors own 51.82% of the company’s stock.

Immunic Price Performance

Shares of NASDAQ IMUX opened at $0.98 on Friday. Immunic has a 52-week low of $0.92 and a 52-week high of $2.11. The firm’s 50-day moving average price is $1.09 and its two-hundred day moving average price is $1.30.

Immunic (NASDAQ:IMUXGet Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). During the same quarter in the prior year, the business earned ($0.51) EPS. On average, analysts predict that Immunic will post -0.94 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on IMUX. HC Wainwright began coverage on shares of Immunic in a report on Monday, November 25th. They issued a “buy” rating and a $10.00 price target on the stock. StockNews.com raised Immunic from a “sell” rating to a “hold” rating in a research report on Friday. Finally, D. Boral Capital restated a “buy” rating and set a $17.00 price target on shares of Immunic in a research note on Tuesday, January 7th. One analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $12.67.

Check Out Our Latest Analysis on Immunic

About Immunic

(Get Free Report)

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

See Also

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.